GlassScriptPhysician profile
Donald Alan Morris
NPI 1336108794
$3,827.91
in general payments reported to CMS, 2019-2025
22 companies · $665 in 2025
The $665 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $708 · 2020: $124 · 2021: $225 · 2022: $564 · 2023: $536 · 2024: $1,006 · 2025: $665.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,207.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $772.19 | 2019-2025 | Argos, Clareon, Clareon Panoptix Pro |
| Bausch & Lomb Americas INC. | $578.88 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Oyster Point Pharma, INC. | $267.38 | 2022-2025 | Tyrvaya, Ryzumvi |
| Mallinckrodt Hospital Products INC. | $254.66 | 2021-2023 | Acthar |
| Abbvie INC. | $236.08 | 2023-2025 | |
| Tarsus Pharmaceuticals, INC. | $201.41 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $194.67 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $192.82 | 2019-2025 | Cequa |
| Glaukos Corporation | $191.42 | 2019-2025 | Idosetr, Idose, Istent Inject Trabecular Micro-Bypass System |
| Allergan, INC. | $172.19 | 2019-2022 | |
| New World Medical,INC. | $166.77 | 2019 | |
| Aerie Pharmaceuticals, INC. | $95.41 | 2019-2021 | |
| Biotissue Holdings INC. | $86.16 | 2019-2023 | |
| Harrow Eye, LLC | $68.75 | 2023-2024 | Vevye |
| Sight Sciences, INC. | $67.63 | 2025 | Sion Surgical Instrument, Omni Surgical System |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $64.73 | 2024-2025 | Iyuzeh |
| Dompe US, INC. | $53.35 | 2024-2025 | Oxervate |
| Kala Pharmaceuticals, INC. | $48.17 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $41.09 | 2019-2020 | |
| Rxsight INC | $33.66 | 2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Shire North American Group INC | $20.89 | 2019 | |
| Mallinckrodt Enterprises LLC | $19.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.